Atlas Trials

A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer

Clinical trial NCT04203719 · UNKNOWN

Trial details

NCT number
NCT04203719
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced Head, Neck and Chest Cancer
Start date
2020-05-09
Primary completion
2020-12-31
Enrollment
140

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.